Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Chakra Biotech Of Malaysia Invests To Attract MNC Drug Testing

This article was originally published in PharmAsia News

Executive Summary

Malaysia's Chakra Biotech plans to invest $8 million in a facility with a neurobehavioral laboratory it expects to begin operating in two months with a staff of 80. The lab is to focus on testing drugs for treating disorders of the central nervous system and is in talks to test drugs for three multinational pharmaceutical companies. CEO Anthony Bishop said Chakra planned to take advantage of a $30 billion market for drug-testing services. (Click here for more

Table

View full table

Tags:
Latest Headlines

AstraZeneca’s Hot Streak Whets Investor Appetite For What’s Next

Sweden's InDex To Stay Afloat Thanks To Mystery Merger Partner

China Biotech Podcast: AACR, BIOSECURE European Perspectives

Gilead Doesn’t See Big M&A In Near-Term, But Eyes Next-Gen Cell Therapies

See All
UsernamePublicRestriction

Register

SC070757

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By